ExodusPoint Capital Management LP Buys Shares of 108,267 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

ExodusPoint Capital Management LP bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 108,267 shares of the company's stock, valued at approximately $857,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Trexquant Investment LP raised its position in Amneal Pharmaceuticals by 93.2% in the 4th quarter. Trexquant Investment LP now owns 462,720 shares of the company's stock valued at $3,665,000 after purchasing an additional 223,158 shares during the last quarter. Geode Capital Management LLC increased its position in Amneal Pharmaceuticals by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 3,813,207 shares of the company's stock valued at $30,207,000 after acquiring an additional 26,536 shares during the period. Diametric Capital LP purchased a new position in shares of Amneal Pharmaceuticals in the 4th quarter valued at approximately $252,000. Alliancebernstein L.P. lifted its stake in shares of Amneal Pharmaceuticals by 2.5% in the 4th quarter. Alliancebernstein L.P. now owns 200,246 shares of the company's stock worth $1,586,000 after acquiring an additional 4,927 shares during the period. Finally, Prudential Financial Inc. grew its holdings in Amneal Pharmaceuticals by 29.6% during the fourth quarter. Prudential Financial Inc. now owns 1,183,781 shares of the company's stock worth $9,376,000 after acquiring an additional 270,200 shares during the period. Hedge funds and other institutional investors own 31.82% of the company's stock.

Insider Transactions at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 80,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total transaction of $712,000.00. Following the completion of the transaction, the director now owns 1,808,886 shares in the company, valued at $16,099,085.40. The trade was a 4.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the firm's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the sale, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15. The trade was a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,160,000 shares of company stock valued at $43,113,200. 26.56% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Price Performance

NASDAQ:AMRX traded up $0.03 during mid-day trading on Wednesday, reaching $7.20. The company's stock had a trading volume of 271,307 shares, compared to its average volume of 1,400,823. The company's fifty day simple moving average is $8.14 and its two-hundred day simple moving average is $8.27. Amneal Pharmaceuticals, Inc. has a twelve month low of $5.18 and a twelve month high of $9.48. The stock has a market cap of $2.23 billion, a P/E ratio of -10.58 and a beta of 1.06.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.03). The firm had revenue of $730.52 million for the quarter, compared to analyst estimates of $708.21 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same quarter in the prior year, the company earned $0.14 earnings per share. Sell-side analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on AMRX. Barclays increased their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a report on Monday, March 3rd. StockNews.com downgraded shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, December 19th. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their target price for the company from $9.00 to $12.00 in a report on Monday, February 24th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $10.80.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.